{"id":"W3132559292","doi":"10.1016/j.jtho.2021.02.009","title":"Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"Merck Sharp and Dohme; Ono Pharmaceutical; PharmaMar; Shionogi; Astellas Pharma; Daiichi-Sankyo; Cancer Research UK; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Amgen; Boehringer Ingelheim; Taiho Pharmaceutical; F. Hoffmann-La Roche; Chugai Pharmaceutical; Roche; Novartis; AbbVie; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Topotecan; Second line; Oncology; Internal medicine; Phase (matter); First line; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001716069,0.0008639288,0.00224336,0.0004165558,0.000335979,0.00148473,0.0007631599,0.0008932486,0.001501877],"category_scores_gemma":[0.00135889,0.000313865,0.001955445,0.0004963278,0.0006423095,0.001117882,0.0002822108,0.00241863,0.0003811078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001166634,"about_ca_system_score_gemma":0.0009846602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001188528,"about_ca_topic_score_gemma":0.002761384,"domain_scores_codex":[0.9993331,0.0003192365,0.00003790122,0.0001019984,0.00009046889,0.0001173936],"domain_scores_gemma":[0.9991203,0.0002455606,0.0002520594,0.00008436599,0.00004440999,0.0002533754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7613052,0.01782802,0.02011664,0.0007392483,0.00442266,0.0001512463,0.0002760374,0.004108943,0.02856387,0.0002564106,0.002087482,0.1601442],"study_design_scores_gemma":[0.4054421,0.4654524,0.1045084,0.0001287423,0.005047402,0.0006473067,0.0002182117,0.00409139,0.009134663,0.0005120626,0.004681196,0.0001361551],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957801,0.002758002,0.0001173388,0.00013231,0.00003431704,0.0001280049,0.000398811,0.0000281316,0.000622999],"genre_scores_gemma":[0.9968621,0.001242827,0.0002386185,0.0001848107,0.00005691682,0.0001103266,0.0007343396,0.00001841267,0.000551742],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00224336,"threshold_uncertainty_score":0.009075522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0525605755118861,"score_gpt":0.4658585770188332,"score_spread":0.4132980015069471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}